title: Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.
abstract: Ibritumomab tiuxetan is a novel radioimmunotherapeutic agent that has a high response rate in relapsed or chemotherapy-refractory CD20+ B-cell non-Hodgkin's lymphoma. Whereas chemotherapy agents can successfully be used multiple times in a given patient, there are few data on the repeated use of radioimmunotherapy in terms of efficacy or morbidity, and no reports as yet involving radioconjugates that target different antigens We report on a patient who was treated successfully with yttrium-90-labeled humanized anti-CD22 monoclonal antibody (90Y-epratuzumab). Upon relapse 3 years later, the patient was treated again with radioimmunotherapy consisting of 90Y-ibritumomab tiuxetan anti-CD20 monoclonal antibody, with a good response and acceptable bone marrow suppression. This case report demonstrates the potential for repeated treatments with radioimmunotherapy agents in patients with chemotherapy-refractory non-Hodgkin's lymphoma.
authors.affiliation: Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia, 19104, USA. detsai@mail.med.upenn.edu
authors.forename: Donald E
authors.initials: DE
authors.lastname: Tsai
authors.forename: Ivan
authors.initials: I
authors.lastname: Maillard
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Schuster
authors.forename: Sunita D
authors.initials: SD
authors.lastname: Nasta
authors.forename: David L
authors.initials: DL
authors.lastname: Porter
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Klumpp
authors.forename: David M
authors.initials: DM
authors.lastname: Goldenberg
authors.forename: Selina M
authors.initials: SM
authors.lastname: Luger
authors.forename: Abass
authors.initials: A
authors.lastname: Alavi
authors.forename: Robert M
authors.initials: RM
authors.lastname: Sharkey
authors.forename: Kenneth B
authors.initials: KB
authors.lastname: Hartzell
authors.forename: Edward A
authors.initials: EA
authors.lastname: Stadtmauer
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000276:immunology*; D018951:Antigens, CD20 / Q000276:immunology*; D000944:Antigens, Differentiation, B-Lymphocyte / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology / Q000473:pathology; D015815:Cell Adhesion Molecules; D018450:Disease Progression; D006801:Humans; D037102:Lectins / Q000276:immunology*; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000379:methods*; D019275:Radiopharmaceuticals; D051918:Sialic Acid Binding Ig-like Lectin 2; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D018951:Antigens, CD20; D000944:Antigens, Differentiation, B-Lymphocyte; C497867:CD22 protein, human; D015815:Cell Adhesion Molecules; D037102:Lectins; D019275:Radiopharmaceuticals; D051918:Sialic Acid Binding Ig-like Lectin 2; D015021:Yttrium Radioisotopes; C448700:epratuzumab; C422802:ibritumomab tiuxetan